Drug Profile
Research programme: antiviral therapy - National Cancer Institute
Latest Information Update: 18 Apr 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class
- Mechanism of Action RNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Herpes simplex virus infections; Varicella zoster virus infections
Most Recent Events
- 18 Apr 2002 No development reported - Preclinical for Herpes simplex virus infections in USA (unspecified route)
- 18 Apr 2002 No development reported - Preclinical for Varicella zoster virus infections in Belgium (unspecified route)
- 18 Apr 2002 No development reported - Preclinical for Varicella zoster virus infections in USA (unspecified route)